Skip to main content
IDWeek 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Stuart H. Cohen, MD

Medical Director of Hospital Epidemiology; Division Chief, Infectious Diseases
University of California, Davis
Sacramento, CA, United States

Stuart H. Cohen, M.D., FIDSA, FSHEA, FACP
Distinguished Professor and Chief
Division of Infectious Diseases
UC Davis School of Medicine
Clinical Director
Department of Hospital Epidemiology and Infection Prevention
UC Davis Health

Stuart H. Cohen is a Distinguished Professor of Internal Medicine and the Chief of the Division of Infectious Diseases at the University of California, Davis Medical Center, Clinical Director for Infection Control and Epidemiology as well as Interim Clinical Director for the Medical Microbiology Lab and the Director of the Antimicrobial Stewardship Program. He finished his ID Fellowship in 1983 at UC Davis and has been board certified in Infectious Diseases since 1983. He was the ID Fellowship Program Director for 20 years and stepped down in 2015 shortly after he was appointed Division Chief. He is a busy clinician who does inpatient and outpatient care including Transplant Infectious Diseases and HIV. He joined IDSA 3 years after finishing his fellowship and has been a Fellow since 1994. He has served on multiple committees, most recently as the Chair of the Fellowship InTraining Exam Committee. He has varied research interests but has focused on Clostridioides difficile infection for over 20 years. He has contrbuted to the field in numerous areas. One of the major works was done with Chris Polage related to diagnostic testing and was one of the papers that led to toxin testing as a critical test for the diagnosis of Clostridioides difficile infection. He has been active in the treatment of Clostridioides difficile with microbiome based therapy. During the COVID pandemic, he led the UC Davis response and has been a contributor to multiple studies regarding therapeutics and healthcare epidemiology including in hospital transmission of SARS-CoV-2. He was also the site Princpal Investigator for the Novavax clinical trial. Currently he was the lead in the Sacramento areas approach to monkeypox. We have been treating all of the local patients with tecovirimat and are involved in vaccine distribution. He is a co-investigator and site PI in a multicenter study of the use of chlorhexidine bathing post-operatively to prevent surgical site infections. He is currently the local PI studying a vaccine for E.coli urinary tract infections. He remains an active educator in the ID fellowship program and the Internal Medicine residency at UC Davis Health.

Disclosure(s): No financial relationships to disclose

Presentation(s):